
Theradaptive, Inc.: A global pharmaceutical firm developing targeted tissue repair therapeutics via THX1 platform.
Theradaptive, Inc., founded with a mission to revolutionize tissue repair, leverages its proprietary THX1 platform to develop advanced therapeutics. The company's core vision is to create safer and more effective treatments by enhancing the targeted delivery of therapeutics, addressing significant unmet medical needs. Theradaptive focuses on global markets, offering innovative solutions that promote native tissue repair through advanced protein engineering.
Notable figures affiliated with Theradaptive include its pioneering scientists and strategic investors who support its groundbreaking research. The company has achieved significant milestones in therapeutic discovery, enhancing the efficacy and safety of protein-based treatments. Theradaptive's impact is evident in its potential to transform the pharmaceutical landscape by providing targeted, effective solutions for complex medical conditions.

Neuraptive Therapeutics
neuraptive.com

Adcentrx Therapeutics
adcentrx.com

Therapyx
therapyxinc.com

Theracos
theracos.com

Adaptive Phage Therapeutics

Juvena Therapeutics

Akttyva Therapeutics
akttyva.com

ProFound Therapeutics
profoundtx.com

Therabron Therapeutics
therabron.com

Empirico
empiricotx.com

Thesan Pharmaceuticals
thesanpharma.com

Theraly Pharmaceuticals

Therini Bio
therinibio.com

Pliant Therapeutics
pliantrx.com

Guardian Therapeutics
Companies similar to Theradaptive include Neuraptive Therapeutics, Adcentrx Therapeutics, Therapyx and Theracos.
Theradaptive was founded in 2016.
Theradaptive's headquarters is located in Frederick, MD, US.
Theradaptive's most recent funding round was for $7.4M (USD) in September 2023.
As of Sep 26, 2023, Theradaptive has raised a total of $33.4M (USD).
Theradaptive has 23 employees as of Feb 4, 2024.